DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gilenya (Fingolimod Hydrochloride) - Current Clinical Trials

 
 



Gilenya Related Clinical Trials

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya [Recruiting]

Gilenya in Amyotrophic Lateral Sclerosis (ALS) [Active, not recruiting]

Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS [Completed]

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Completed]

Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Completed]

Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya [Recruiting]

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod [Terminated]

An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis [Completed]

Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. [Recruiting]

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis [Terminated]

Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome [Recruiting]

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis [Completed]

Safety and Efficacy of Fingolimod in MS Patients in China [Withdrawn]

Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis [Recruiting]

Fingolimod in Schizophrenia Patients [Recruiting]

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma [Recruiting]

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis [Completed]

Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON) [Terminated]

Study of FTY720 in Patients With Uveitis [Withdrawn]

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants [Recruiting]

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression [Terminated]

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis [Completed]

OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis [Recruiting]

FTY720 in Patients With Primary Progressive Multiple Sclerosis [Completed]

Efficacy and Safety of FTY720 for Acute Stroke [Recruiting]

Fingolimod -Response According to Coping - Evaluation [Completed]

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) [Completed]

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 [Recruiting]

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis [Recruiting]

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) [Completed]

ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon [Withdrawn]

Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program [Completed]

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis [Recruiting]

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS) [Completed]

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy [Recruiting]

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change [Completed]

Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya [Active, not recruiting]

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms [Active, not recruiting]

Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod [Recruiting]

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies [Recruiting]

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. [Recruiting]

Fingolimod Effect on Cytokine and Chemokine Levels [Not yet recruiting]

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis [Completed]

MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) [Recruiting]

Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects. [Completed]

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis [Completed]

Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod [Recruiting]

A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma [Completed]

Pregnancy Registry Trial [Recruiting]

Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers [Completed]

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. [Completed]

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Completed]

Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Completed]

Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients [Completed]

Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis [Recruiting]

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod [Recruiting]

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis [Completed]

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant [Completed]

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant [Completed]

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant [Completed]

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation [Completed]

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Completed]

PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod [Recruiting]

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Completed]

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients [Completed]

Exploratory Study to Assess Clinical Response to Gilenyaź (Fingolimod) in Relapsing Remitting Hispanic Multiple Sclerosis Forms [Recruiting]

Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis [Completed]

Long-term Follow-up of Fingolimod Phase II Study Patients [Recruiting]

Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720) [Recruiting]

Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate [Recruiting]

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenyaź [Recruiting]

A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 [Completed]

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies [Recruiting]

Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS [Withdrawn]

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study [Recruiting]

Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation [Not yet recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017